The second Phase III failure of an antisense drug in a week - this time, Isis Pharmaceuticals Inc.'s first-generation alicaforsen for Crohn's disease - might have cast some doubt on the once-ballyhooed field, but Isis is sticking with the compound for ulcerative colitis on the basis of success in three Phase II studies. (BioWorld Today) Read More
